文献速递淋巴瘤

来那度胺维持治疗对比安慰剂用于一线R-CHOP治疗缓解的老年弥漫大B细胞淋巴瘤患者

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
PubMed 文献 · J Clin Oncol · 2017-04-20

这项随机III期试验纳入650例60至80岁、经6或8周期R-CHOP诱导达完全缓解或部分缓解的初治弥漫大B细胞淋巴瘤或其他侵袭性B细胞淋巴瘤患者,比较来那度胺25 mg/d(每28天周期用21天,共24个月)与安慰剂维持治疗。中位随访39个月时,来那度胺组中位无进展生存期未达到,安慰剂组为58.9个月(HR 0.708,95%CI 0.537-0.933,P=0.01)。中位随访52个月时总生存两组相似(HR 1.218,95%CI 0.861-1.721,P=0.26)。

要点

  • 来那度胺维持24个月显著延长老年DLBCL患者无进展生存期(HR 0.708,P=0.01)。
  • 中位随访52个月时总生存两组相似(HR 1.218,P=0.26)。
  • 来那度胺组3/4级中性粒细胞减少56% vs 安慰剂组22%,皮肤反应5% vs 1%。

核心结论

  • 在经R-CHOP诱导达完全缓解或部分缓解的老年弥漫大B细胞淋巴瘤患者中,来那度胺维持治疗24个月显著延长无进展生存期。

研究设计与样本

  • 随机III期试验,纳入650例60至80岁、初治弥漫大B细胞淋巴瘤或其他侵袭性B细胞淋巴瘤、经6或8周期R-CHOP后达完全缓解或部分缓解的患者。
  • 随机分配至来那度胺25 mg/d或安慰剂,每28天周期用21天,共24个月。
  • 主要终点为无进展生存期。

主要发现

  • 主要分析(2015年12月)时中位随访39个月,来那度胺组中位无进展生存期未达到 vs 安慰剂组58.9个月(HR 0.708,95%CI 0.537-0.933,P=0.01)。
  • 结果在各分析亚组(如男性 vs 女性、年龄校正国际预后指数0或1 vs 2或3、年龄小于70岁 vs ≥70岁)、R-CHOP后缓解(部分缓解 vs 完全缓解)及分组时正电子发射断层扫描状态(阴性 vs 阳性)中一致。
  • 中位随访52个月(2016年10月)时,总生存两组相似(HR 1.218,95%CI 0.861-1.721,P=0.26)。
  • 来那度胺组 vs 安慰剂组最常见的3或4级不良事件为中性粒细胞减少(56% vs 22%)和皮肤反应(5% vs 1%)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Lenalidomide, an immunomodulatory agent, has shown activity in DLBCL. This randomized phase III trial compared lenalidomide as maintenance therapy with placebo in elderly patients with DLBCL who achieved a complete response (CR) or partial response (PR) to R-CHOP induction. Methods Patients with previously untreated DLBCL or other aggressive B-cell lymphoma were 60 to 80 years old, had CR or PR after six or eight cycles of R-CHOP, and were randomly assigned to lenalidomide maintenance 25 mg/d or placebo for 21 days of every 28-day cycle for 24 months. The primary end point was progression-free survival (PFS). Results A total of 650 patients were randomly assigned. At the time of the primary analysis (December 2015), with a median follow-up of 39 months from random assignment, median PFS was not reached for lenalidomide maintenance versus 58.9 months for placebo (hazard ratio, 0.708; 95% CI, 0.537 to 0.933; P = .01). The result was consistent among analyzed subgroups (eg, male v female, age-adjusted International Prognostic Index 0 or 1 v 2 or 3, age younger than 70 v ≥ 70 years), response (PR v CR) after R-CHOP, and positron emission tomography status at assignment (negative v positive). With longer median follow-up of 52 months (October 2016), overall survival was similar between arms (hazard ratio, 1.218; 95% CI, 0.861 to 1.721; P = .26). Most common grade 3 or 4 adverse events associated with lenalidomide versus placebo maintenance were neutropenia (56% v 22%) and cutaneous reactions (5% v 1%), respectively. Conclusion Lenalidomide maintenance for 24 months after obtaining a CR or PR to R-CHOP significantly prolonged PFS in elderly patients with DLBCL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Thieblemont C, Tilly H, Gomes da Silva M, et al. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. J Clin Oncol. 2017. PMID: 28426350. doi:10.1200/JCO.2017.72.6984

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。